Hims & Hers Health Inc. ($HIMS) Stock Forecast: Up 5.8% Today

What is Hims & Hers Health Inc.?

Hims & Hers Health, Inc. (HIMS) operates in the telehealth and personalized health and wellness products sector. The stock experienced a significant bullish movement in the market today.

Why is Hims & Hers Health Inc. going up?

HIMS stock is up 5.8% on Apr 17, 2026 18:01

• Hims & Hers stock exhibited bullish movement driven by positive sentiment surrounding the company. Factors contributing to this include:
• The significant gift of shares by the CEO, signaling confidence in the company's future and growth potential.
• Bullish sentiments expressed by analysts and traders on TradingView, supported by strong earnings and technical indicators, influencing increased investor interest.
• Positive market trends, reflected in gains seen in the S&P 500 and Nasdaq, likely also impacted HIMS stock.
• The company's emphasis on telehealth and personalized health products aligns with the current market demand for digital health solutions, further bolstering the bullish movement.
• Investor focus on Hims & Hers, alongside other prominent stocks like Microsoft and Tesla, indicates a broader interest in the technology and healthcare sectors, fueling positive momentum in the market.

HIMS Price Chart

HIMS Technical Analysis

HIMS News

Allbirds, Hims & Hers, Microsoft, Xanadu Quantum And Tesla: Why These 5 Stocks Are On Investors' Radars Today

Major U.S. indices had a mixed day, with the Dow Jones Industrial Average slipping, and the S&P 500 and Nasdaq seeing gains. Several stocks, including Allbirds, Hims & Hers, Microsoft, Xanadu Quantum Technologies, and Tesla, garnered significant investor attention due to company-specific news and market trends. Allbirds pivoted to AI, Xanadu Quantum benefited from Nvidia's new AI model for quantum computing, and Microsoft capitalized on a risk-on session and AI software developments.

https://www.sahmcapital.com/news/content/allbirds-hims-hers-microsoft-xanadu-quantum-and-tesla-why-these-5-stocks-are-on-investors-radars-today-2026-04-16

Hims & Hers Health, Inc. Class A Trade Ideas — LS:A2QMYY

This article compiles various trade ideas and analyses for Hims & Hers Health, Inc. (HIMS) stock from TradingView users. Traders offer diverse perspectives ranging from bullish long positions based on strong earnings and technical indicators to bearish short setups due to overbought conditions or potential pullbacks, and even strategies involving selling options. The analyses include technical indicators, target prices, stop-loss levels, and risk-reward ratios.

https://www.tradingview.com/symbols/LS-A2QMYY/ideas/page-7/

Hims & Hers (NYSE: HIMS) CEO makes 845,866-share bona fide gift

Hims & Hers Health, Inc. CEO Andrew Dudum reported a bona fide gift of 845,866 shares of Class A Common Stock on April 9, 2026, according to a recent Form 4 filing. The transaction involved two gift entries of 422,933 shares each, with no price paid, indicating estate and family wealth planning rather than market trading. Following these gifts, Dudum directly holds 887,684 shares and maintains indirect holdings through various family and GRAT trusts.

https://www.stocktitan.net/sec-filings/HIMS/form-4-hims-hers-health-inc-insider-trading-activity-595be87407a1.html

Trending Today

Hims & Hers Health Inc. Price History

20.02.2026 - HIMS Stock was down 8.2%

• Concerns were raised by a former FDA commissioner regarding the effectiveness of Hims & Hers' proprietary weight-loss drug, which utilizes different technology compared to products from Novo Nordisk.
• Despite a renewed collaboration with Novo Nordisk, investor jitters were likely caused by an investigation into potential securities fraud conducted by the Portnoy Law Firm, contributing to the bearish trend.
• The negative sentiment surrounding HIMS stock was amplified by a substantial sell-off triggered when Novo Nordisk terminated their partnership in weight-loss drug sales.
• In the short term, investor confidence may have been affected by the company's decision to cease sales of compounded GLP-1 drugs and focus on the distribution of branded versions.

18.02.2026 - HIMS Stock was down 5.5%

• An investigation into possible securities fraud concerning Hims & Hers Health, Inc.'s suspension of sales for its branded weight-loss medication was conducted by the Portnoy Law Firm. This likely sparked investor concerns and led to the bearish market activity.
• The termination of a partnership by Novo Nordisk in relation to weight-loss medication sales might have prompted a substantial sell-off, contributing to the overall pessimism surrounding the stock.
• Hims & Hers Health, Inc.'s acquisition of Eucalyptus, an Australian digital health organization, to expand its international presence, could have instilled uncertainty about integration expenses and regulatory requirements, further impacting the stock's performance.
• Despite a recent 57% rise in share price, a reevaluation of the company's worth by investors and considerations about regulatory oversight may have also influenced the negative market trend witnessed today.

07.03.2026 - HIMS Stock was down 5.1%

• HIMS stock displayed a significant downward trend today.
• Concerns among investors have been elevated by an investigation and lawsuit initiated by Kahn Swick & Foti, LLC, surrounding alleged misconduct by Hims & Hers Health, particularly in relation to its termination of partnership with Novo Nordisk.
• The negative market sentiment towards HIMS can be attributed to legal actions and regulatory scrutiny, including accusations of deceptive marketing and non-compliance with laws regarding compounded drugs.
• Despite potential growth prospects stemming from the Novo Nordisk partnership, uncertainties and legal issues faced by Hims & Hers Health have overshadowed the positive developments, leading to the downward movement in the market.

02.03.2026 - HIMS Stock was down 7.9%

• The stock of HIMS experienced a significant drop due to potential securities law violations and lawsuits related to the sale of compounded drugs, leading to investor concerns and a bearish sentiment.
• Despite a recent pullback, the company is trading at a discount to its intrinsic value and analyst price targets, indicating a lack of confidence in its future performance.
• The internal realignment by Vanguard, reporting 0 shares beneficially owned, might have added to the negative sentiment surrounding HIMS, signaling a lack of institutional support.
• The regulatory scrutiny and increased competition faced by Hims & Hers Health Inc. could further impact its stock price, highlighting the importance of monitoring price action for tactical trading decisions.

25.02.2026 - HIMS Stock was down 5.5%

• The bearish movement in HIMS stock today might be linked to the insider trading activity of the Chief Financial Officer, Oluyemi Okupe, who recently sold a significant number of shares.
• Recent positive developments, such as a partnership renewal with Novo Nordisk for weight loss drugs and a stock upgrade by a securities firm, have been overshadowed by an ongoing investigation into alleged misrepresentations and securities law violations.
• Despite the company's potential for growth through strategic partnerships, HIMS is currently undervalued according to a recent valuation analysis.
• The launch of a waitlist for FDA-approved weight-loss medications with Novo Nordisk is seen as a positive step, but it may not have been sufficient to counteract the negative impact of insider trading and legal scrutiny, leading to today's bearish market movement for HIMS.

17.03.2026 - HIMS Stock was up 5.8%

• Hims & Hers stock exhibited bullish movement driven by positive sentiment surrounding the company. Factors contributing to this include:
• The significant gift of shares by the CEO, signaling confidence in the company's future and growth potential.
• Bullish sentiments expressed by analysts and traders on TradingView, supported by strong earnings and technical indicators, influencing increased investor interest.
• Positive market trends, reflected in gains seen in the S&P 500 and Nasdaq, likely also impacted HIMS stock.
• The company's emphasis on telehealth and personalized health products aligns with the current market demand for digital health solutions, further bolstering the bullish movement.
• Investor focus on Hims & Hers, alongside other prominent stocks like Microsoft and Tesla, indicates a broader interest in the technology and healthcare sectors, fueling positive momentum in the market.

08.03.2026 - HIMS Stock was down 5.5%

• The CFO's sale of shares and exercising of options may have signaled a lack of confidence in the company's future prospects, contributing to the bearish movement.
• The investigation initiated by a legal firm, and the investor lawsuit over alleged misconduct have likely raised concerns among investors, leading to a negative sentiment towards the stock.
• The termination of the partnership with another company and the allegations of deceptive marketing and failure to adhere to laws regarding compounded drugs have cast a shadow on Hims & Hers Health's reputation, impacting its stock performance negatively.
• The combination of insider selling, legal troubles, and ethical concerns has created a perfect storm of bad news for Hims & Hers Health, resulting in the bearish market movement observed today.

31.02.2026 - HIMS Stock was up 5.8%

• Despite recent challenges and regulatory scrutiny, Hims & Hers Health Inc. (HIMS) experienced a bullish movement with its stock today.
• The company's valuation, currently trading at a discount to its intrinsic value, is backed by fast revenue growth and increasing profitability.
• A prior investigation into potential securities law violations by a legal firm and FDA restrictions caused a significant stock pullback.
• Today's bullish sentiment may stem from renewed investor confidence in the company's long-term growth prospects and strategic actions to address regulatory concerns.

24.02.2026 - HIMS Stock was down 5.3%

• The renewal of the partnership with Novo Nordisk for weight loss drugs showcased growth potential. However, questions about the legality and safety of Hims & Hers compounded drugs post-partnership termination caused investor worry.
• An investigation by Kahn Swick & Foti, LLC into alleged misrepresentations and securities law violations by Hims & Hers Health's officers and directors added further doubt, impacting the market negatively.
• Despite the introduction of a waitlist for FDA-approved weight-loss medications with Novo Nordisk, concerns about legal issues and valuation likely influenced the stock's performance.
• Insider selling of shares by Hims & Hers Health's Chief Legal Officer through a pre-arranged trading plan may have also affected investor confidence, indicating potential internal issues within the company.

12.02.2026 - HIMS Stock was down 7.1%

• The end of a partnership with Novo Nordisk, a securities class action lawsuit, and accusations of violating laws related to mass sales of compounded drugs and deceptive marketing are believed to have influenced the decline in HIMS stock.
• Although HIMS resolved the partnership issue with Novo Nordisk to provide branded obesity drugs, ongoing uncertainties and potential near-term margin challenges, as pointed out by Morningstar, may have impacted investor confidence.
• Real-time signal analysis suggesting increased downside risk and Novo Nordisk's decision to sell its weight-loss drug through the telehealth platform might have contributed to the negative market sentiment surrounding HIMS.
• Investors could be reacting to the changes in supply and regulatory requirements resulting from the shift to branded therapies from compounded alternatives, affecting Hims & Hers Health's investment outlook and possibly raising concerns about its future performance.

13.03.2026 - HIMS Stock was up 5.5%

• The CEO's generous donation of 845,866 shares of Class A Common Stock may have reassured investors, indicating a steadfast dedication to the company's growth and prosperity.
• Despite a 6.1% decrease following an expansion in GLP-1 access through a partnership with Novo Nordisk, this development could be perceived as a strategic move to enhance the company's offerings in medically supervised weight management.
• The ongoing fraud investigation by the Schall Law Firm might have initially caused uncertainty, leading to a decline in share prices. Nevertheless, today's bullish trend suggests that investors may hold a positive outlook on the company's ability to address these legal issues effectively.
• Various discussions about technical analysis and trade opportunities might have influenced the optimism, as traders could identify potential long positions based on strong earnings and technical signals.

27.02.2026 - HIMS Stock was down 5.1%

• Today's bearish movement in HIMS stock may be linked to an ongoing investigation into potential securities law violations related to compounded GLP-1 active pharmaceutical ingredients by the Schall Law Firm, and a lawsuit from Novo Nordisk concerning the sale of compounded weight loss drugs.
• The CFO of Hims & Hers Health, Oluyemi Okupe, engaged in insider trading by selling a substantial amount of shares, possibly contributing to the negative market sentiment.
• Despite recent positive developments such as partnerships and the renewal of the weight loss drug partnership with Novo Nordisk, analysts have noted concerns about the stock's valuation, suggesting it may be undervalued compared to its current price. This perceived disparity could be a factor fueling the sell-off in the stock.